EWTX — Edgewise Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Edgewise Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 281 | 352 | 318 | 470 | 530 |
| Prepaid Expenses | |||||
| Total Current Assets | 284 | 357 | 327 | 475 | 543 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.912 | 9.85 | 12.7 | 11.1 | 9.22 |
| Other Long Term Assets | |||||
| Total Assets | 285 | 367 | 340 | 487 | 553 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 10.5 | 16.6 | 16.8 | 23.9 | 27.4 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 10.8 | 20.4 | 21.2 | 27.6 | 30.3 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 274 | 347 | 319 | 459 | 522 |
| Total Liabilities & Shareholders' Equity | 285 | 367 | 340 | 487 | 553 |
| Total Common Shares Outstanding |